PRESS RELEASE published on 03/07/2025 at 08:29, 1 year 8 months ago Inside Information / Operations of the issuer (acquisitions, sales...) GenSight Biologics announces c. €0.9 million financing round for innovative gene therapy program. Financing from existing investors supports LUMEVOQ access for patients. Business update includes 2024 annual results and working capital statement Financing Business Update Gene Therapy GenSight Biologics LUMEVOQ
BRIEF published on 02/27/2025 at 09:02, 1 year 8 months ago GenSight Biologics: 2024 Financial Results and Outlook Gene Therapy Cash Management Financial Results 2024 Future Financing LUMEVOQ Compassionate Access
PRESS RELEASE published on 02/27/2025 at 08:57, 1 year 8 months ago Inside Information / News release on accounts, results GenSight Biologics reports estimated full-year 2024 consolidated financial results. Cash runway extended to early April 2025. Resumption of Compassionate Access Program expected in April 2025 Financial Results 2024 GenSight Biologics Cash Runway Compassionate Access Program
BRIEF published on 02/12/2025 at 07:35, 1 year 9 months ago GenSight Biologics Reports Positive Five-Year Outcomes for LUMEVOQ® Gene Therapy Gene Therapy LUMEVOQ® Visual Acuity Safety Profile REFLECT Study
PRESS RELEASE published on 02/12/2025 at 07:30, 1 year 9 months ago Inside Information / Other news releases GenSight Biologics reports 5-year efficacy and safety results for LUMEVOQ® gene therapy in REFLECT study with sustained visual improvement and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity REFLECT Study
BRIEF published on 01/23/2025 at 18:50, 1 year 9 months ago GenSight Biologics: Financial Report and Outlook GenSight Biologics Capital Increases LUMEVOQ® Compassionate Access Treasury 2024
PRESS RELEASE published on 01/23/2025 at 18:45, 1 year 9 months ago Inside Information / News release on accounts, results GenSight Biologics reports end-of-year cash position and provides business update, including successful capital increases and ongoing review of LUMEVOQ dossier Business Update Cash Position GenSight Biologics Capital Increases LUMEVOQ Dossier
BRIEF published on 01/15/2025 at 07:35, 1 year 9 months ago GenSight Biologics Reports Long-Term Results for LUMEVOQ® Gene Therapy GenSight Biologics LUMEVOQ® Visual Acuity Leber's Hereditary Optic Neuropathy
PRESS RELEASE published on 01/15/2025 at 07:30, 1 year 9 months ago Inside Information / Other news releases GenSight Biologics announces the publication of 5-year outcomes for patients treated with LUMEVOQ® gene therapy, showing sustained bilateral improvement in visual acuity and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity Safety Profile
BRIEF published on 01/13/2025 at 11:31, 1 year 10 months ago Heights Capital Management exceeds 5% stake in GenSight Biologics Capital Increase Shares And Voting Rights GenSight Biologics Heights Capital Management Capital Participation
Published on 11/14/2026 at 12:56, 2 hours 59 minutes ago Gabriel Announces Dismissal of ICSID Annulment Application
Published on 11/14/2026 at 01:30, 14 hours 25 minutes ago NuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published on 11/14/2026 at 00:40, 15 hours 15 minutes ago BEACN Announces Annual General and Special Meeting Results
Published on 11/14/2026 at 00:35, 15 hours 20 minutes ago American Hotel Income Properties REIT LP Reports Q3 2026 Results
Published on 11/14/2026 at 00:00, 15 hours 55 minutes ago SLAM Announces Proposed Extension of Warrant Expiry Dates
Published on 11/13/2026 at 23:24, 16 hours 30 minutes ago EQS-Adhoc: ASOS PLC: Repurchase of £90m of 2028 Convertible Bonds
Published on 11/13/2026 at 21:52, 18 hours 2 minutes ago EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:08, 20 hours 46 minutes ago EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 18:04, 21 hours 50 minutes ago EQS-Adhoc: CHAPTERS Group AG: Capital Increase from Authorized Capital Resolved
Published on 11/13/2026 at 11:35, 1 day 4 hours ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/12/2026 at 23:12, 1 day 16 hours ago Belgrano continues the implementation of its public share buyback offer (OPRA)
Published on 11/12/2026 at 18:36, 1 day 21 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/10/2026
Published on 11/12/2026 at 18:00, 1 day 21 hours ago Information concerning the total number of voting rights and shares in the share capital as of November 12, 2026
Published on 11/12/2026 at 17:40, 1 day 22 hours ago Financial information for the period ended 30 September 2026
